150 related articles for article (PubMed ID: 35405309)
21. Hypoxic induction of vasculogenic mimicry in hepatocellular carcinoma: role of HIF-1 α, RhoA/ROCK and Rac1/PAK signaling.
Zhang JG; Zhou HM; Zhang X; Mu W; Hu JN; Liu GL; Li Q
BMC Cancer; 2020 Jan; 20(1):32. PubMed ID: 31931758
[TBL] [Abstract][Full Text] [Related]
22. Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder.
Sauzeau V; Beignet J; Bailly C
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740379
[TBL] [Abstract][Full Text] [Related]
23. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway.
Liu S; Yu M; He Y; Xiao L; Wang F; Song C; Sun S; Ling C; Xu Z
Hepatology; 2008 Jun; 47(6):1964-73. PubMed ID: 18506888
[TBL] [Abstract][Full Text] [Related]
24. PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma.
Wu Y; Zhang Y; Qin X; Geng H; Zuo D; Zhao Q
Pharmacol Res; 2020 Oct; 160():105195. PubMed ID: 32916254
[TBL] [Abstract][Full Text] [Related]
25. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.
Guo Y; Kenney SR; Muller CY; Adams S; Rutledge T; Romero E; Murray-Krezan C; Prekeris R; Sklar LA; Hudson LG; Wandinger-Ness A
Mol Cancer Ther; 2015 Oct; 14(10):2215-27. PubMed ID: 26206334
[TBL] [Abstract][Full Text] [Related]
26. A20 interacts with mTORC2 to inhibit the mTORC2/Akt/Rac1 signaling axis in hepatocellular carcinoma cells.
Wang X; Xiao Y; Dong Y; Wang Z; Yi J; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Cancer Gene Ther; 2023 Mar; 30(3):424-436. PubMed ID: 36411371
[TBL] [Abstract][Full Text] [Related]
27. The cycloartane triterpenoid ADCX impairs autophagic degradation through Akt overactivation and promotes apoptotic cell death in multidrug-resistant HepG2/ADM cells.
Sun H; Huang M; Yao N; Hu J; Li Y; Chen L; Hu N; Ye W; Chi-Shing Tai W; Zhang D; Chen S
Biochem Pharmacol; 2017 Dec; 146():87-100. PubMed ID: 29074104
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma.
Wang SM; Ooi LL; Hui KM
Clin Cancer Res; 2011 Sep; 17(18):6040-51. PubMed ID: 21825042
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells.
Wu L; Cai C; Wang X; Liu M; Li X; Tang H
FEBS Lett; 2011 May; 585(9):1322-30. PubMed ID: 21482222
[TBL] [Abstract][Full Text] [Related]
30. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
31. Annexin A5 regulates hepatocarcinoma malignancy via CRKI/II-DOCK180-RAC1 integrin and MEK-ERK pathways.
Sun X; Liu S; Wang J; Wei B; Guo C; Chen C; Sun MZ
Cell Death Dis; 2018 May; 9(6):637. PubMed ID: 29802377
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
33. Identification of
Permtermsin C; Lalchungnunga H; Nakjang S; Casement J; Ogle LF; Reeves HL; Strathdee G; Shukla R
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047360
[TBL] [Abstract][Full Text] [Related]
34. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
35. Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma.
Chang CY; Lin SC; Su WH; Ho CM; Jou YS
Oncogene; 2012 May; 31(21):2640-52. PubMed ID: 21996735
[TBL] [Abstract][Full Text] [Related]
36. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.
Rosenblatt AE; Garcia MI; Lyons L; Xie Y; Maiorino C; Désiré L; Slingerland J; Burnstein KL
Endocr Relat Cancer; 2011 Apr; 18(2):207-19. PubMed ID: 21118977
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
39. TIPE1 induces apoptosis by negatively regulating Rac1 activation in hepatocellular carcinoma cells.
Zhang Z; Liang X; Gao L; Ma H; Liu X; Pan Y; Yan W; Shan H; Wang Z; Chen YH; Ma C
Oncogene; 2015 May; 34(20):2566-74. PubMed ID: 25043299
[TBL] [Abstract][Full Text] [Related]
40. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
